A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy
2016 ◽
Vol 22
(1)
◽
pp. 126-135
◽
2012 ◽
Vol 55
(11)
◽
pp. 717
◽
2015 ◽
Vol 77
(2)
◽
pp. 339-347
◽
2017 ◽
Vol 47
(12)
◽
pp. 1175-1181
◽